Evidence map›Paper›PMID 34259909›Full record

ArticleJournal of neurology2022

Adult-onset mitochondrial movement disorders: a national picture from the Italian Network.

V Montano, D Orsucci, V Carelli, C La Morgia, M L Valentino, C Lamperti, S Marchet, O Musumeci, A Toscano, G Primiano and 10 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Rethinking Mitochondrial Parkinson's Disease in the α-Synuclein Seed Amplification Assays Era.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Red Flags in Primary Mitochondrial Diseases: What Should We Recognize?International journal of molecular sciences · 2023
    Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 1 country.

V MontanoDepartment of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
D OrsucciUnit of Neurology, San Luca Hospital, Lucca, Italy.
V CarelliIRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica, Bologna, Italy.
C La MorgiaIRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica, Bologna, Italy.
M L ValentinoIRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica, Bologna, Italy.
C LampertiUO Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy.
S MarchetUO Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy.
O MusumeciUnit of Neurology and Neuromuscular Disorders, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
A ToscanoUnit of Neurology and Neuromuscular Disorders, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
G PrimianoFondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
F M SantorelliMolecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit, IRCCS Stella Maris Foundation, Pisa, Italy.
C TicciMolecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit, IRCCS Stella Maris Foundation, Pisa, Italy.
M FilostoDepartment of Clinical and Experimental Sciences, ASST Spedali Civili Brescia and NeMO-Brescia Clinical Center for Neuromuscular Diseases, University of Brescia, Brescia, Italy.
A RubegniMolecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit, IRCCS Stella Maris Foundation, Pisa, Italy.
T MonginiDepartment of Neurosciences, University of Torino, Turin, Italy.
P ToninDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Clinical Neurology, University of Verona, Verona, Italy.
S ServideiFondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
R CeravoloDepartment of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
G SicilianoDepartment of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
Michelangelo MancusoDepartment of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy. michelangelo.mancuso@unipi.it.ORCID http://orcid.org/0000-0003-2738-8562
University of Pisa · ITFondazione Stella Maris · ITIstituto delle Scienze Neurologiche di Bologna · ITFondazione IRCCS Istituto Neurologico Carlo Besta · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Messina · ITUniversity of Brescia · ITUniversity of Turin · ITUniversity of Verona · IT

Funding

EJPRD GENOMITFondazione Telethon GSP16001Fondazione Telethon GUP09004Ministero della Salute RF-2016-02361495Regione Emilia-Romagna ER-MITO
6 · The paper itself

Abstract

introductionBoth prevalence and clinical features of the various movement disorders in adults with primary mitochondrial diseases are unknown.

methodsBased on the database of the "Nation-wide Italian Collaborative Network of Mitochondrial Diseases", we reviewed the clinical, genetic, neuroimaging and neurophysiological data of adult patients with primary mitochondrial diseases (n = 764) where ataxia, myoclonus or other movement disorders were part of the clinical phenotype.

resultsAtaxia, myoclonus and movement disorders were present in 105/764 adults (13.7%), with the onset coinciding or preceding the diagnosis of the mitochondrial disease in 49/105 (46.7%). Ataxia and parkinsonism were the most represented, with an overall prevalence at last follow-up of 59.1% and 30.5%, respectively. Hyperkinetic movement disorders were reported in 15.3% at last follow-up, being the less common reported movement disorders. The pathogenic m.8344A > G and POLG variants were always associated with a movement disorder, while LHON variants and mtDNA single deletions were more commonly found in the subjects who did not present a movement disorder. The most common neuroimaging features were cortical and/or cerebellar atrophy, white matter hyperintensities, basal ganglia abnormalities and nigro-striatal degeneration. Almost 70% of patients with parkinsonism responded to dopaminergic therapy, mainly levodopa, and 50% with myoclonus were successfully treated with levetiracetam.

conclusionMovement disorders, mainly ataxia and parkinsonism, are important findings in adult primary mitochondrial diseases. This study underlies the importance of looking for a mitochondrial etiology in the diagnostic flowchart of a movement disorder and may help direct genetic screening in daily practice.

Indexed as

Mitochondrial DiseasesMovement DisordersMyoclonusParkinsonian DisordersHumansPhenotypeAtaxiaMitochondrial disordersMovement disordersParkinsonism

Identifiers

PMID34259909
PMCPMC8857085
OpenAlexW3179658744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.